Form 4: SpringWorks Therapeutics COO Sells Shares Under 10b5-1 Trading Plan

SpringWorks Therapeutics' Chief Operating Officer, Badreddin Edris, sold a total of 20,000 shares of common stock on December 3, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics, sold 11,966 shares of common stock at a weighted average price of $41.7802 on December 3, 2024.
• He also sold 8,034 shares of common stock at a weighted average price of $42.2447 on the same day.
• These sales were executed under a pre-established trading plan adopted on February 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
• The total number of shares sold was 20,000.
• Following these transactions, Mr. Edris still directly owns 209,600 shares of SpringWorks Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive under a pre-arranged plan, which is neither positive nor negative in itself. The sentiment is neutral.

Risks

• Sales by company executives can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and sales under 10b5-1 plans are generally viewed as routine and pre-planned.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a common practice across the pharmaceutical and biotech industry, with companies like Pfizer, Amgen, and Gilead Sciences also having executives who utilize such plans.
• The volume of shares sold by Mr. Edris is not unusual for an executive of a company of SpringWorks' size and market capitalization.

Stakeholder Impact

• The stock sale may have a minor impact on the share price, but it is unlikely to have a significant effect on other stakeholders.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, insider trading, Form 4, 10b5-1, stock sale, Badreddin Edris, Chief Operating Officer